Human neural progenitors from a variety of sources present new opportunities to model aspects of human neuropsychiatric disease in vitro. Such in vitro models provide the advantages of a human genetic background combined with rapid and easy manipulation, making them highly useful adjuncts to animal models. Here, we examined whether a human neuronal culture system could be utilized to assess the transcriptional program involved in human neural differentiation and to model some of the molecular features of a neurodevelopmental disorder, such as autism. Primary normal human neuronal progenitors (NHNPs) were differentiated into a post-mitotic neuronal state through addition of specific growth factors and whole-genome gene expression was examined throughout a time course of neuronal differentiation. After 4 weeks of differentiation, a significant number of genes associated with autism spectrum disorders (ASDs) are either induced or repressed. This includes the ASD susceptibility gene neurexin 1, which showed a distinct pattern from neurexin 3 in vitro, and which we validated in vivo in fetal human brain. Using weighted gene co-expression network analysis, we visualized the network structure of transcriptional regulation, demonstrating via this unbiased analysis that a significant number of ASD candidate genes are coordinately regulated during the differentiation process. As NHNPs are genetically tractable and manipulable, they can be used to study both the effects of mutations in multiple ASD candidate genes on neuronal differentiation and gene expression in combination with the effects of potential therapeutic molecules. These data also provide a step towards better understanding of the signaling pathways disrupted in ASD.
Introduction
Genetic advances in human neuropsychiatric conditions have provided us with a new window through which we can begin to study and understand these complex diseases. Perhaps this is most evident in autism spectrum disorders (ASDs) wherein recent studies have identified many relatively rare monogenic causes of ASD, as well as some common variants associated with the disease. [1] [2] [3] [4] [5] [6] [7] These studies have revealed that autism, like other neurodevelopmental disorders is genetically very heterogeneous, involving many potential mutational mechanisms and potentially distinct molecular pathways. 2, 4, 8 Although this complexity may at first appear daunting, the study of monogenic ASD risk genes has proven to be instrumental for understanding the basic biology of these genes during brain development. Thus, even though many of the more Mendelian forms of ASDs are rare, they provide an important opportunity to begin to understand the normal function of these autism risk genes and loci through their manipulation in transgenic mice. [9] [10] [11] Mouse models serve an important function in understanding the role of these risk genes in brain development and conserved behavioral traits. Although extremely useful for understanding monogenic disorders, one drawback to the use of mouse as a model is the challenge of perturbing multiple genes to mimic the genetics of disease. In addition, lengthy breeding and gestational times can also make the experimental design prolonged and less amenable to high-throughput screening. On the other hand, models such as zebrafish (Danio rerio) do allow for rapid and high-throughput in vivo screening of genes and small molecules. 12 So, although animal models are necessary for examining circuits and behavior correlates, it is likely that no single model of a complex neurodevelopmental disease will completely recapitulate the human disorder. In fact, the study of gene expression pathways provides mounting evidence that human and mouse have significant areas of divergence.
Comparison of global differences in gene co-expression between human and mouse revealed many instances of human-specific patterns of expression; several of these modules are associated with human neurodegenerative disorders that are challenging to model in mice. 13 Moreover, a specific comparison of human and chimpanzee signaling pathways downstream of FOXP2, a transcription factor involved in speech and language, again identified differential gene expression and co-expression networks that could be characterized in vitro.
14 Therefore, even the most closely related species to humans, the chimpanzee, has evolved different signaling networks in some cases. Thus, the use of human-derived model systems should be considered an important adjunct for a complete understanding of neuropsychiatric disorders involving human higher cognition and behavior. In addition, both of the studies mentioned above, 13, 14 and many others [15] [16] [17] [18] [19] [20] highlight how the identification of gene co-expression networks can uncover new functional insights-including genes involved in neurodegeneration or genes involved in human language and cognition. Therefore, the employment of a network approach to any gene expression data set generated from a human model system is a significant step towards a complete understanding of how gene interactions promote a particular function.
One new approach for modeling disease-related phenotypes in human tissue is the use of induced pluripotent stem cells. 21 Using this technique, fibroblasts from patients are converted to the cells of interest and the resultant phenotypes are analyzed. At least one study has used induced pluripotent stem cells to study Rett syndrome, a disorder within the autism spectrum. 22 Such a process is a step in the right direction as the cells are from human and originate from specific patient populations. However, working with these cells can be challenging because they need to be manipulated genetically to reprogram into a pluripotent state and the conversion to neurons can be lengthy and low in efficiency. 23 There is little doubt though that a thorough comparative study of the gene expression profile of neurons from induced pluripotent stem cells to neural tissue from the same individuals will be very useful.
Another potential model system that also has not been well tested, are human cells that are derived from brain tissue and grown in vitro. For the study of neurodevelopmental disorders, the use of embryonic brain tissue from early brain development provides the advantage of capturing the correct time points in development when genetic and environmental insults are thought to be causative. [24] [25] [26] We therefore developed a human neural progenitor system to assess the functional genomics of both normal human neuronal development and autism using human fetal brain tissue. These normal human neural progenitors, or normal human neuronal progenitors (NHNPs), are derived from early human embryos at B8-19 gestational weeks. These cells have previously been utilized to examine neuronal phenotypes during Wnt signaling, 27 as well as targets of the transcription factor FOXP2, recapitulating patterns observed in vivo.
14 Here, we find that during the differentiation process of NHNPs, many genes already previously linked to ASD are highly co-expressed, as assessed using whole genome microarrays. Moreover, a number of ASD genes demonstrate conserved patterns of gene co-expression during the time course of differentiation. As little is known about the transcriptional program accompanying human neuronal differentiation, the comprehensive analysis of gene expression reported here provides a foundational tool for assessing the interaction of numerous signaling cascades in the pathophysiology of ASD and other neurodevelopmental disorders. The ability to easily manipulate gene expression in these cells 14 also makes NHNPs attractive for studying the functional consequences of altered signaling pathways involved in ASD in human neurons.
Materials and methods
Cell culture NHNP cells were obtained from Lonza (Walkersville, MD, USA) or generated as previously described. 28, 29 See Supplementary Table 1 for detailed cell line characteristics. Cells were used at a low passage, 30 typically around passage 20. Proliferating cells were grown on tissue culture plates coated with 5 mg ml À1 of fibronectin and 50 mg ml À1 of poly-ornithine. Growth media of proliferating cells was Neurobasal A media (Invitrogen, Carlsbad, CA, USA) containing 2.5 mM heparin, 10% BIT (Stem-Cell Tech, Vancouver, BC, Canada), 1% glutamax (Invitrogen) and 2% penicillin and streptomycin. Growth media was supplemented every other day with 10 ng ml À1 of epidermal growth factor and basic fibroblast growth factor. For differentiation followed by RNA extraction, 100 000 cells were plated per well of a six-well tissue culture dish coated with poly-ornithine and laminin. For differentiation followed by immunocytochemistry, 5000 cells were plated per well of a 24-well tissue culture dish containing glass coverslips coated with poly-ornithine and laminin (5 mg ml
À1
). Two days after plating, undifferentiated samples were collected for the zero time point. At this time, we initiated the differentiation process and fed cells with a 50% media change containing retinoic acid (10 ng ml À1 ), neurotrophin-3 (10 ng ml À1 ), brain-derived neurotrophic factor (10 ng ml
) and potassium chloride (KCl) (10 mM). We continued to provide a 50% media change containing these growth factors every other day until the samples were collected. Samples were harvested at three time points after initiating the differentiation process: 2 weeks, 4 weeks and 8 weeks.
Genetic association data All human transcripts from build hg18 that map to a unique location in the genome were utilized. SNPs from the Illumina 550k platform (San Diego, CA, USA) were analyzed from 20k upstream of the transcript start site to 10k downstream of the transcript end. P values for association with ASD were drawn from the discovery phase of, 6 using 780 multiplex families from the Autism Genetics Research Exchange. Data are included in Supplementary Table 6 .
Genotyping
Genomic DNA was extracted from four independently generated cell lines using Qiagen's DNeasy kit (Valencia, CA, USA) according to the manufacturer's instructions. Approximately 1.5 mg of genomic DNA from each line was hybridized to Illumina's Human CytoSnp-12 genotyping arrays. SNP genotypes were filtered for quality and analyzed for gender in PLINK. 31 Race determinations were made in PLINK using multi-dimensional scaling. Existing genotype data 6 and self-reported race information from the Autism Genetics Research Exchange cohort were used to establish racial groups. CNVs were called using PennCNV 32 with wave adjustment and subjected to the following quality filters: log R ratio s.d. < 0.28, B allele frequency drift < 0.002, waviness factor < 0.05.
Immunocytochemistry
Coverslips were fixed in 2% paraformaldehyde in phosphate-buffered saline at RT for 10 min and permeabilized in 0.5% Triton-X at RT for 10 min. Next, non-specific staining was blocked using Tris-buffered saline containing 10% normal donkey serum and 0.1% Triton-X at RT for 1 h. Incubations with primary antibodies diluted in blocking solution were done at 4 1C overnight. Incubations with secondary antibodies diluted in blocking solution were done at RT for 1 h. Cell nuclei were stained using 46-diamidino-2-phenyl indole. Images were captured using a Zeiss Axio Imager.D1 (Thornwood, NY, USA). Antibodies utilized were as follows: rabbit anti-nestin In situ hybridization In situ hybridization was performed as previously described 33 using human fetal brain as template. Primers are included in Supplementary 
Microarray analysis
Total RNA was extracted using Qiagen's RNeasy kit, according to the manufacturer's instructions. Samples were hybridized to Illumina Human Ref8-v3 microarrays. Quantile normalization was conducted as previously described.
14 Heatmaps and dendrograms were generated using the limma package in R (http:// www.R-project.org). Gene ontology (GO) and disease association analysis was done as previously described 14 using DAVID (http://david.abcc.ncifcrf.gov) and all of the probes on the microarrays as background. Gene expression data have been deposited in the NCBI Gene Expression Omnibus (GEO; http:// www.ncbi.nlm.nih.gov/geo) and are accessible using GEO accession number GSE28046.
Quantitative reverse transcriptase PCR
Complementary DNA was generated from total RNA using random hexamers and Superscript III (Invitrogen). Real-time PCR was conducted using Sybr-Rox SuperMix (Bio-Rad, Hercules, CA, USA) and an HT-7900 (Applied Biosystems, Foster City, CA, USA). Intron-spanning primers are detailed in Supplementary Table 8 .
Weighted gene co-expression network analysis
Weighted gene co-expression analysis was conducted as previously described. 14, 15 See Supplementary Methods for R code used to generate and analyze the network. Genes denoted as being implicated in ASD were based on the SFARI gene database (http://gene.sfari.org), and are demarcated or used for analysis as in Figure 
Results
We first assessed the feasibility of using NHNPs as a model system for studying neuronal differentiation. Low passage NHNPs were utilized for all experiments, and when the cells were provided with growth-inducing signals in the form of epidermal growth factor and basic fibroblast growth factor they maintained a proliferative state (Figure 1a ; see Materials and methods). Although the doubling time of these human cells is prolonged compared with embryonic rodent neural progenitors, the NHNPs can be kept in culture in a proliferative state for at least a year, if not longer (data not shown). We then tested the characteristics of the NHNPs after receiving differentiation cues, which was achieved by replacing epidermal growth factor and basic fibroblast growth factor with retinoic acid to promote cell cycle exit (see Materials and methods). In addition, we also supplemented the media with brain-derived neurotrophic factor, neurotrophin-3 and KCl to provide supportive growth factors and appropriate conductive ions for neurons. Under these conditions, we found a threefold decrease in proliferating, Ki67 þ cells after 2 weeks (Figure 1b) .
We next assessed whether we could generate neurons under these differentiation conditions. We conducted immunostaining for nestin, a marker of proliferating progenitors, 34 Tuj1, a marker of immature neurons, 35 MAP2, a marker of mature neurons; 36 and GFAP, a marker of glia. 37 We found a significant decrease in nestin-positive cells and a significant increase in both Tuj1 and MAP2-positive cells with 4 weeks of differentiation (Figures 1c-f and data not shown). Tuj1-positive cells represent about 50% of the cells in culture at 4 weeks (Figure 1f ), whereas the number of GFAP-positive cells stayed consistent throughout differentiation (data not shown). Thus, using our differentiation conditions, we can efficiently differentiate human neural progenitors into post-mitotic neurons. Moreover, based on gene expression profiling (see below), the NHNPs may differentiate into a number of neuronal types including both excitatory and inhibitory neurons. This is evidenced by an increase in expression of genes such as DRD3, DRD4, GABBR1, GABRB3, GAD1, GAD2, GRIK1, GRIN1, GRM2, GRM3, SLC23A1 and SLC6A1 for example (Supplementary Table 2 ).
Next, we characterized this process of differentiation by conducting whole-genome microarray analyses on a time course of differentiating NHNPs. We selected four time points to assess: time 0 or undifferentiated cells, 2 weeks, 4 weeks and 8 weeks of differentiation (T0, D2, D4 and D8). These time points were chosen for the following reasons: D2 because we observed a significant decrease in proliferation at this time (Figure 1b ), D4 because there was a significant increase in Tuj1 at this time Table showing the number of genes changing at each time point comparison using microarrays with thresholds of an false discovery rate (FDR)p0.01 and fold change±1.5.
( Figure 1f ) and D8 because it represented a period of time twice as long as D4 for direct comparison with the D2 to D4 transition during neuronal maturation. Four biological replicates from each time point were included for analysis. Hierarchical clustering demonstrates that the biological replicates clustered with one another and that the time point most different from the other three when considering expression of all genes was the one containing the undifferentiated cells (Supplementary Figure 1A) . When only the top 500 most variable genes were analyzed, T0 and D2 clustered separately from D4 and D8 (Supplementary Figure 1B) , suggesting that the genes changing the most during the time course represent differential patterns of expression between the early and late phase of differentiation. This pattern also suggested that neural specification may be entrained at time point D4.
To investigate the possibility that D4 was a critical time point in NHNP differentiation, we examined the genes changing at D4 compared with T0. Using criteria of a false discovery rate p0.01 together with a fold change of ± 1.5, 2218 genes increased in abundance and 2209 genes decreased at D4 compared with T0 (Figure 1g ). Known key markers of neuronal differentiation increased at this time point including MAP1B,
ephrins (EFNB3, EFNB1), 41 and semaphorins (SEMA5A, SEMA5B, SEMA6C). 42 In addition, the expression pattern of genes in the NHNPs is consistent with the cells being derived from forebrain progenitors. For example, SP8 and SHH are expressed in the proliferating cells, 43 whereas RELN, SOX5, TBR1, BCL11B (CTIP2), CALB2 and NGFR are induced with differentiation. 44 Supplementary Table 2 lists all of the genes changing at the D4 time point. GO analysis revealed that the most significantly enriched categories for upregulated genes were nervous system development, neurogenesis, neuron differentiation and synaptogenesis although those for downregulated genes were cell cycle and mitosis (Table 1 and Supplementary Table  3) , consistent with cessation of the proliferative state. Disease association data were also derived from the DAVID database based on GO classifications (see Materials and methods). All of these data were derived from gene expression profiling in one cell line. However, we found significant overlap (P < 3.73E-85-P = 0.0) using similar differentiation parameters with two different lines of NHNPs (line 4, Supplementary Table 1 and an additional third line, data not shown).
We next compared the genes changing at D4 to those changing at least 1.3-fold in human brain in vivo between 18 and 23 gestational weeks 45 to determine to what extent the in vitro changes recapitulated those observed in vivo. Out of a potential 575 genes that are available for overlap comparison using our criteria for fold change, 167 genes are increased (P = 7.56E-89) and 202 are decreased (P = 5.64E-114) under both maturation conditions (Supplementary Table 4) , an overlap of about two-thirds. These data are even more remarkable considering that the microarrays utilized are different, only a relatively short period of in vivo development is represented and the in vivo data for comparison consists of pooled data that includes subcortical areas. Thus, these data support the hypothesis that 4 weeks of differentiation of NHNPs recapitulates the appropriate timing for robust neuronal differentiation in human cells and tissue and reflects molecular processes relevant to in vivo development.
To assess whether this model system could be appropriate for understanding ASD, we crossreferenced two lists of genes with strong evidence for association with ASD 8, 46 with the genes changing during D4 (false discovery ratep0.01 and fold change ± 1.3). Out of a total of 28 genes implicated in ASD, we found a significant overlap of genes going both up (seven genes; P = 2.6E-02) and down (seven genes; P = 2.4E-02) at D4 ( Table 2) . Next, we examined whether we could independently confirm the genes changing on the microarrays using real-time quantitative reverse transcriptase PCR. Using a threshold of 1.5-fold change, we confirmed B80% of the genes tested (Table 2) . Therefore, the microarrays indicate that a significant number of ASD candidate genes are regulated during human neuronal differentiation in vitro.
One interesting observation was that neurexin 1 (NRXN1), an autism and schizophrenia susceptibility gene, and one probe for neurexin 3 (NRXN3) change in opposite directions on the microarrays. We subsequently confirmed by quantitative reverse transcriptase PCR that NRXN1 was upregulated during NHNP differentiation (Figure 2a ) consistent with its known role in synaptic function. 47, 48 However, using three different primer pairs to different NRXN3 isoforms, we found NRXN3 was downregulated (Figure 2a) . This was somewhat surprising, as there was no previous suggestion that these two highly homologous genes had different functions or expression patterns in human brain. To see if this corresponded to the in vivo situation, we performed in situ hybridization in human fetal brain, which remarkably confirmed these results. NRXN3 is expressed in areas of progenitor cells in human fetal brain, whereas NRXN1 is expressed in areas of post-mitotic neurons (Figures 2b-i) . Inspection of the mouse in situ hybridization data in Allen Brain Atlas also shows a similar pattern using different probes (http:// www.brain-map.org/). This proof of principle demonstrates how a simple in vitro human system can be used to guide in vivo discovery. These particular data suggest that NRXN3 has a previously unknown role in neural progenitor biology, distinct from canonical neurexin function at the synapse, which is likely conserved from mice to humans.
Although distinct up or down changes in gene expression are important parameters of any cellular process, we have begun to appreciate that gene expression data sets contain other inherent patterns of gene co-expression that can be mined, so as to reach new functional insights. 49 Specifically, we have used weighted gene expression co-expression network analysis 50 as previously described 14,15 to provide a systems-level view of the organization of the neural transcriptome. Genes that are highly co-expressed are grouped into 'modules.' A module's correspondence to different aspects of function, such as neuronal phenotypes, sample characteristics (disease vs control), or cellular organelles is determined by analysis of the module eigengene or first principle component. 15, 50 In addition, central or 'hub' genes can be identified within modules. 15, 20 Weighted gene co-expression network analysis of the NHNP differentiation time course identified a total of 22 modules, 14 of which could be easily characterized (Supplementary Table 5 ). Four modules were clearly associated with differentiation over time throughout the entire time course from T0 through D8. Four other modules correlated best with the undifferentiated cells (T0), although one module eigengene was highly correlated with D2 and another with D8. The module whose eigengene is most correlated with D2 (the green module) is of interest as these genes are likely those involved in defining the onset of neural specification and the cessation of proliferation and cell division. The D8, or sea green, module may contain genes involved in neuronal maturation and phenotype maintenance. Finally, four other modules represented the transition from D2 to D4. We hypothesized that these modules likely contain genes that are critical for the differentiation process, as D4 was the time point when a significant increase in Tuj1 positive cells was observed (Figure 1 ) and the GO of genes changing at D4 was enriched for CNS differentiation.
We next sought to determine whether there may be shared biological processes or pathways between distinct ASD risk genes in an unbiased manner using weighted gene co-expression network analysis. To broaden the number of genes available for this analysis, we queried the SFARI gene database for the most inclusive list of genes with a relationship to ASD (http://gene.sfari.org). Although many of these genes may currently have a weak association to ASD, inclusion of as many genes as possible in this analysis should yield networks of genes with the greatest potential for ASD-related gene co-expression and provides an unbiased view. Using the SFARI database, we demarcated 224 genes with a potential role in ASD. Ninety of these genes overlapped with the top 6000 most-connected genes in the current gene expression data set and were included in the network analysis. Although these 90 genes were distributed across 17 modules (Supplementary Table  6 ), there were four modules with a particular concentration of ASD genes: the royal blue module (with 18 ASD genes), the pink module (with 17 ASD genes), the turquoise module (with eight ASD genes) and the black module (with 7 ASD genes) (Figure 3 ). This non-random concentration of genes within this cohort of modules suggested some shared pathways and previously un-recognized connections between ASD susceptibility genes.
The module eigengene of the royal blue module is related to T0; thus these genes are most related to the proliferative state of the neural progenitors. Not surprisingly, therefore, the top enriched GO categories for the royal blue module include cell adhesion, nervous system development and neurogenesis (Supplementary Table 3 in the top 250 connections within this module (Supplementary Figure 2A) . The pink module contains genes related to differentiation across the entire time course. Therefore, these genes are most correlated with the process of differentiation. The pink module contains genes that are enriched in cell cycle GO categories (P = 2.29E-05) and axon guidance (P = 1.74E-02) (Supplementary Table 3 ). Visualization of the top connected genes in the pink module reveals ABAT, PLAUR and SCN1A, all ASD candidate genes, as being among the most connected genes within the module (Figure 3b) . Interestingly, MET, another ASD gene that likely coordinates with PLAUR to transmit hepatocyte growth factor signaling, 8, 51 is also contained within the pink module, but does not make the cutoff for visualization.
The black and turquoise modules contain genes involved in the D2 to D4 transition; therefore, these genes are likely to be important for early neuronal differentiation. The black module is enriched for genes involved in signal transduction (P = 4.53E-07). Two out of the seven ASD candidate genes, NRXN1 and GLRA2, can be visualized among the most connected genes in the black module (Figure 3c ). The most significant GO categories for the turquoise module are neuron projection (P = 1.27E-06) and nervous system development (P = 5.41E-06). Both NRXN1 and SLC9A6 are highly connected within the turquoise module (Figure 3d ). Strikingly, of the almost 600 gene connections to ASD genes within the four ASD modules, only seven, or 1%, were previously known or could be surmised based on the literature, although the remaining 590 are novel, demonstrating the power of this analysis.
Another manner with which to identify potentially novel ASD signaling pathways is to focus on the interconnectedness of only the known ASD genes. For example, upon filtering for only known ASD-gene related connections in the turquoise module, not only are the ASD genes always connected by one node or fewer, but now other genes are prioritized, such as the cell adhesion genes CTNNA2 and TAGLN (Supplementary Figure 2A ). Using an identical approach with the royal blue module shows inclusion of 17 out of the 18 ASD genes in the module (Supplementary Figure 2B) . In addition, well-characterized genes such as SEMA5B and GFAP are easily identifiable as connected among these ASD genes. This level of connectivity is non-random, as the mean overall network connectivity degree is 17 times less than the ASD genes alone, and permutation analysis (See Supplementary Methods) shows that the ASD gene connectivity is much more significant compared with a randomized list of genes of the same size (P = 0). This demonstrates that within the complex and enormous process of neuronal differentiation, specific aspects and pathways are more clearly associated with ASD.
To validate whether there were any genetic associations increased in these four modules, we first examined the literature using GO. The royal blue module is enriched for genes with a genetic association with schizophrenia (although this P value did not reach our threshold for significance; P = 5.86E-02). These data make sense in light of some of the overlap in the genetic origins of schizophrenia and ASD. [52] [53] [54] In contrast, other neurological disease genes were not significantly enriched, for example, dementia (P = 1.1E-01), Parkinson's disease (P = 3.9E-01) or bipolar disorder (P = 4.9E-01). The pink module also contains genes that are enriched in schizophrenia (P = 2.12E-02). The black module is enriched for genes implicated in autism (P = 2.45E-02), bipolar disorder (P = 2.50E-04) and Alzheimer's disease (P = 4.05E-02). Interestingly, the GO analysis reports four additional genes in the autism category that were not included in the SFARI gene database as potential ASD candidate genes (BDNF, TH, HLA-DRB4 and NRG1). This highlights that the criteria for inclusion as an 'autism gene' can vary among databases. Finally, the turquoise module is enriched for genes involved in panic disorder (P = 1.28E-02) and attention deficit disorder (P = 1.56E-02). Thus, these data illustrate that there are likely overlapping signal networks during brain development that are disrupted in various permutations to lead to a number of neuropsychiatric disorders.
Recent studies have shown that although genomewide association studies may not reveal strongly associated genes with large effect sizes in neuropsychiatric disease, overall there may be a weaker signal spread across many genes, as has been demonstrated in schizophrenia and bipolar disorder. 6, 7, 55 Thus, it has been suggested that identification of potentially causal pathways could be a means with which to increase power to detect genetic association. To further assess whether there is independent genetic evidence for pathway enrichment, we tested for enhancement of genetic association signals for ASD within the four modules defined above. When the genes used for network analysis were analyzed for genetic association to ASD over 50% of genes with a P value < 1.0E-02 fell into one of these four modules (Supplementary Table 6 ). Although this percentage of genes is not statistically enriched, it provides another level of information for prioritizing unannotated genes that are highly connected to known ASD genes in these modules.
Discussion
The use of human neural progenitors is an important asset for uncovering the genomic patterns of expression in normal human neuronal differentiation and for the study of neuropsychiatric diseases. These cells recapitulate the morphology and markers of differentiation observed in other model systems. However, the use of a few cell markers is limiting, and screening the cells one gene at a time for possible usefulness in the study of a particular disease is tedious. Wholegenome expression profiling is a powerful tool for viewing the entire transcriptional program of a model system under various conditions. Transcriptional profiling has proven extremely informative in the study of many diseases of the CNS as well as in understanding the development and evolution of the brain. 49, 56 We therefore employed a model system of human neuronal cells in combination with whole genome profiling and observed an enrichment of the expression of the genes and signaling pathways involved in ASD, and to a lesser extent other psychiatric disorders with a neurodevelopmental origin, such as schizophrenia. The expression of many of these genes is modulated during neuronal differentiation, especially the early phase of proliferation and the transition to a post-mitotic neuron (T0, D2, and D4), lending unbiased support to the neurodevelopmental origin of ASD. 57 Moreover, ASD genes cluster non-randomly in modules of gene coexpression leading to the potential identification of additional genes with links to ASD. The ease with which gene expression can be manipulated in these cells 14 makes them an attractive tool for studying signaling pathways involved in ASD and other neurodevelopmental disorders.
As mentioned above, the expression pattern of genes such as SHH and RELN in the NHNPs suggests that the cells are derived from forebrain progenitors. As one of the underlying pathologies of ASD is thought to be a developmental disconnection syndrome involving frontal-cortical and frontal-subcortical pathways, 25, 58, 59 the use of cells derived from human fetal cortex provides a potentially powerful and efficient method of examining signaling pathways disrupted in the disease. Moreover, it has also been postulated that ASD is a disorder of axon outgrowth and/or neuronal migration due to the number of cell adhesion molecules that have been implicated in the disorder. 60, 61 In line with this, we have found a significant enrichment of genes involved in cell adhesion that are changing with differentiation (Supplementary Table 3 ) such as CDH1, FBLN2, NRG1, several laminins and numerous protocadherins. In addition, cell adhesion genes are also highly enriched within all four ASD modules identified and cell adhesion is the most significantly enriched biological process category in the royal blue module (Supplementary Table 7) , which is also enriched in ASD candidate susceptibility genes. Parsing the gene expression data to identify groups of genes involved in a particular cellular function should prove useful as the genetic causes of many of the subtypes of ASD are uncovered. For example, these data can be connected to future genes associated with immune dysfunction or head circumference in ASD. In addition, perturbation of ASD genes can reveal potential shared common pathways within the rubric of the normal network topology.
Here, we study ASD as a prototypical neurodevelopmental disorder for the examination of signaling pathways. Many of the genes associated with ASD have known roles in normal brain development and have been associated with other neuropsychiatric diseases such as schizophrenia. 54, 62, 63 Thus, this model system should also serve the study of other neurodevelopmental disorders such as epilepsy or intellectual disability well. To this end, we have uncovered at least one module of gene co-expression containing an enrichment of epilepsy genes, 64 the pink module, which is also one of the ASD-associated modules identified (Supplementary Table 6 ). This is not surprising given the high co-morbidity of these neurodevelopmental disorders, with between 10-25% of ASD patients experiencing seizures or epilepsy. 65 In addition, genetic data support common causal etiologies for these disorders in several cases. [66] [67] [68] [69] [70] Moreover, GO analyses highlights an enrichment of genes with known associations to schizophrenia or other neuropsychiatric disorders.
The application of network analysis to these data can yield important biological insights. Not only does weighted gene co-expression network analysis highlight the interconnectedness of known ASD genes in this model system (Supplementary Figure 2) , it also serves to uncover potentially novel genes that may be affected in the disorder. By conducting our own analysis of publicly available ASD association data, we show that the majority of the most significant SNPs are associated with genes in our four ASD modules (Supplementary Table 6 ; See Materials and methods). These data illustrate that the combination of genetic and genomic data is a powerful tool for identifying new genes in a disorder, particularly for those that might not make a statistical threshold using only one of the methods. For example, although CTNNA2 has been previously associated with schizophrenia 71 and attention deficit hyperactivity disorder, 72 it has no known association with ASD. However, we find it co-expressed with five ASD genes in the turquoise module (CACNA1C, FRMPD4, HS3ST5, NRXN1 and SLC9A6) and exhibiting a suggestive association signal with ASD (4.77E-04). Thus, our analysis would suggest that CTNNA2 has a high probability of having a role in ASD and is a good candidate for re-sequencing in affected patients. In addition to using genetic association data for prioritizing candidate genes, future studies can employ the wealth of gene dosage information in ASD becoming available (e.g. 1, 2 ) to further rank genes in terms of potential pathogenicity.
In addition, we have previously shown that coexpression can be used to annotate gene function. 15, 17 For example, highly co-expressed genes in the human brain transcriptome are also physically co-expressed at the protein level in an adult human neural stem cell niche. 15 Through the principle of guilt by association we can identify and annotate new gene functions. This is based on the hypothesis that similar expression levels among the most highly co-expressed genes in a module are the result of shared regulatory mechanisms. Thus, it is likely that some of the genes co-expressed with the ASD genes in the NHNPs are also key physical partners of the ASD genes in performing certain intrinsic neurobiological features in vivo. This fits with both the synapse and developmental dysconnection models of ASD. Genes correlated with known ASD genes found at the synapse such as NRXN1 73 and RIMS3 74 could themselves be key players in synapse biology. For example, both NRXN1 and SLC9A6 are co-expressed with FLJ30596 (or c5orf33). Currently, there is nothing known about the biology of FLJ30596, however, the expression of SLC9A6 in endosomal vesicles 75 and NRXN1 at the synapse suggests that FLJ30596 may also have some role in synaptic function. Remarkably, we also find that NRXN3 shows an inverse expression pattern to NRXN1, suggesting a role in progenitor biology, which is validated in vivo in human fetal brain. In a similar vein, genes correlated with known ASD genes that are integral in axon pathfinding and hence cortico-cortico connections such as EPHA6,
76
NRP2, 77 and SEMA5A 78 (Supplementary Table 6 ) may themselves be involved in such processes. Thus, the network approach to gene expression analysis may not only identify novel disease-related genes but also may point to the functional role of previously uncharacterized genes.
One area of neuropsychiatric research in need of increased innovation is the discovery of novel therapeutics. Understanding the genes involved in a disorder is a necessary first step; however, having an appropriate model within which to test new drugs is the next critical step. The use of the NHNP system fulfills both criteria. Here, we have demonstrated that there are robust gene expression changes during the differentiation process that follow what is known in vivo in other model organisms as well as in developing human fetal brain. Although we have found significant overlap with these model systems and in vivo expression, the expression of some genes that do not agree (for example, genes going in the opposite direction in Supplementary Table 4) may provide insight into the limitations of this model system and should also be considered in future functional studies. In particular, the effects of processes such as imprinting on cultured cells versus intact or dissociated tissue is an important caveat of this study that may be able to be teased apart using this information. Nonetheless, many of the genes in agreement are not only important for normal differentiation, but are also disrupted or are co-expressed with genes that are disrupted in ASD. Combining these data with previously published 6 and ongoing genome-wide association studies in ASD and other neuropsychiatric diseases 79 will solidify the role of particular genes and pathways in the disease. Moreover, as the cells are genetically tractable through modification by lentiviral overexpression or knockdown, multiple genes can be modified simultaneously to mimic the genetic heterogeneity of diseases such as ASD. Then together with highthroughput chemical library screenings, 80 therapeutics for particular genetic signatures can be rapidly tested. This combinatorial approach therefore is particularly advantageous over animal models where only one or a few genes can be modified concurrently, or highthroughput chemical screening is time intensive.
The combination of these human tools with non-human models clearly provides a synergistic approach for elucidating the signaling cascades important in both normal human brain development as well as in neuropsychiatric disorders. Data sets such as the one presented here will identify new diseaserelated genes and present opportunities for the testing and development of personalized therapeutics.
